Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TEM

Tempus AI Inc

May 08 • 04:00PM ET

49.86

+0.39 0.79 %

Healthcare • Health Information Services • USA • Mid • NASD

May 08, 1:08 AMTempus AI prices upsized $400 million offering of convertible senior notes

Peers: EVH HCAT IQV VEEV NTRA CERT ILMN HQY RXRX SDGR

| Held by: ARKK VTI VB ARKG BAI VBK VXF IBB IWP JTEK

Index	-	P/E	-	EPS (ttm)	-1.72	Insider Own	41.34%	Shs Outstand	174.18M	Perf Week	-9.35%
Market Cap	8.95B	Forward P/E	-	EPS next Y	-0.09	Insider Trans	-1.78%	Shs Float	105.25M	Perf Month	12.91%
Enterprise Value	9.62B	PEG	-	EPS next Q	-0.14	Inst Own	53.48%	Short Float	26.34%	Perf Quarter	-9.20%
Income	-302.91M	P/S	6.56	EPS this Y	39.52%	Inst Trans	8.32%	Short Ratio	5.15	Perf Half Y	-39.39%
Sales	1.36B	P/B	21.46	EPS next Y	74.91%	ROA	-16.47%	Short Interest	27.73M	Perf YTD	-15.56%
Book/sh	2.32	P/C	14.00	EPS next 5Y	-	ROE	-81.58%	52W High	104.32 -52.20%	Perf Year	-23.55%
Cash/sh	3.56	P/FCF	-	EPS past 3/5Y	10.57% 1.21%	ROIC	-17.59%	52W Low	41.73 19.48%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	58.29% 46.57%	Gross Margin	62.22%	Volatility	7.43% 6.75%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.06	EPS Y/Y TTM	62.77%	Oper. Margin	-18.75%	ATR (14)	3.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.15	Sales Y/Y TTM	69.82%	Profit Margin	-22.20%	RSI (14)	45.67	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.31	EPS Q/Q	-77.97%	SMA20	-5.94%	Beta	3.96	Target Price	68.60
Payout	-	Debt/Eq	3.17	Sales Q/Q	36.12%	SMA50	-1.07%	Rel Volume	2.15	Prev Close	49.47
Employees	3800	LT Debt/Eq	3.14	Earnings	May 05 AMC	SMA200	-25.52%	Avg Volume	5.39M	Price	49.86
IPO	Jun 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.87% 0.77%	Trades		Volume	11,592,363	Change	0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Upgrade	TD Cowen	Hold → Buy	$65
Apr-13-26	Initiated	Jefferies	Underperform	$35
Feb-19-26	Initiated	Mizuho	Outperform	$100
Feb-17-26	Initiated	Robert W. Baird	Outperform	$59
Dec-02-25	Resumed	Morgan Stanley	Overweight	$85
Oct-21-25	Downgrade	TD Cowen	Buy → Hold	$88
Oct-20-25	Initiated	Canaccord Genuity	Buy	$110
Sep-02-25	Initiated	H.C. Wainwright	Buy	$90
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74
Nov-11-24	Downgrade	Stifel	Buy → Hold	$45 → $65
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $60
Aug-12-24	Initiated	Piper Sandler	Neutral	$40
Jul-09-24	Initiated	William Blair	Outperform
Jul-09-24	Initiated	TD Cowen	Buy	$50
Jul-09-24	Initiated	Stifel	Buy	$45

Show Previous Ratings

May-08-26 12:59AM	Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes (Business Wire)
May-07-26 07:11AM	Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense (Business Wire) -7.53%
May-06-26 09:31AM	Why The Dip In TEM Stock Is A Buying Window (Trefis)
May-05-26 08:21PM	Tempus AI, Inc. Q1 2026 Earnings Call Summary (Moby)
04:01PM	Tempus Reports First Quarter 2026 Results (Business Wire)
08:30AM	Loading…
Apr-29-26 08:30AM	Tempus to Host Inaugural Investor Day on May 29, 2026 (Business Wire)
Apr-28-26 08:30AM	Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026 (Business Wire)
Apr-23-26 08:30AM	Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine (Business Wire) -7.33%
Apr-21-26 08:30AM	Tempus to Report First Quarter 2026 Financial Results on May 5 (Business Wire)
Apr-15-26 08:30AM	Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring (Business Wire) +13.89%
Apr-14-26 08:30AM	Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026 (Business Wire) +7.72%
Apr-13-26 09:58AM	Nike downgraded, Starbucks upgraded: Wall Street's top analyst calls (The Fly) +7.08%
08:30AM	Tempus Launches Automated "Active Follow-Up" Service to Support Guideline-Concordant Care (Business Wire)
Apr-09-26 08:30AM	Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE (Business Wire) -7.03%
Apr-08-26 04:01PM	Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
08:57AM	Loading…
Mar-26-26 08:57AM	Cathie Wood's Ark Dumped More Meta Stock-and Loaded Up on Another AI Stock Instead (Barrons.com)
06:34AM	Daiichi Sankyo and Tempus AI collaborate on ADC clinical development (Pharmaceutical Business Review)
04:36AM	Meta Stock Dumped by Cathie Wood. Her ARK Funds Go Big On This AI Play Instead. (Barrons.com)
Mar-24-26 03:01PM	Tongcheng Travel Holdings Ltd (FRA:TEM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Mar-17-26 08:30AM	Tempus and Blood Cancer United Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries (Business Wire)
Mar-11-26 08:30AM	Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings (Business Wire)
Mar-10-26 01:33PM	Hims and Hers Expands Consumer-Focused Digital Health Platform (Zacks)
Mar-09-26 08:52AM	Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026? (Zacks)
Mar-07-26 07:11AM	Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine (Insider Monkey)
Mar-05-26 08:44AM	TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? (Zacks)
Mar-04-26 06:00PM	Is Tempus AI, Inc. (TEM) A Good Stock To Buy Now? (Insider Monkey)
Mar-03-26 02:33PM	AI-Powered Tempus Inks New Multi-Year Merck Deal (Benzinga)
12:19PM	Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes (PR Newswire)
08:30AM	Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine (Business Wire)
Mar-01-26 08:00AM	Consumer Tech News (Feb 23-27): US-Taiwan Trade Tensions Escalates, Amazon Invests $12B In US & More (Benzinga)
10:48AM	Loading…
Feb-26-26 10:48AM	TEM vs. ILMN: Which MedTech Stock Offers Greater Upside? (Zacks)
08:30AM	Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference (Business Wire)
Feb-25-26 09:20PM	Cathie Wood Is Buying The Tempus AI Dip, Ark Snaps Up Stock Worth $11 Million (Benzinga) -7.32%
09:44AM	Tempus AI Posts 83% Revenue Growth Yet Stumbles on Full Year Profitability Target (24/7 Wall St.)
08:30AM	Tempus AI, Inc. Q4 2025 Earnings Call Summary (Moby)
07:26AM	TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market (Zacks)
01:07AM	Tempus AI Q4 Earnings Call Highlights (MarketBeat)
12:02AM	Tempus AI Inc (TEM) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Feb-24-26 08:19PM	AMD, Zeta Global, MercadoLibre, Tempus AI And Workday: Why These 5 Stocks Are On Investors' Radars Today (Benzinga)
07:30PM	Tempus AI (TEM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
05:32PM	Tempus AI Stock Drops Despite Q4 Earnings Beat: Details (Benzinga)
04:01PM	Tempus Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-23-26 10:33AM	Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week (Benzinga)
07:46AM	AppLovin Surges 11% While Tempus AI and Micron Also Outpace Most AI Stocks (24/7 Wall St.)
07:21AM	Here's How Tempus AI Is Tapping the Imagining Space (Zacks)
Feb-22-26 08:30AM	Consumer Tech News (Feb 16-20): Big Techs To Boost AI in India, EV Policy Shifts & More (Benzinga)
Feb-20-26 10:55AM	Hims & Hers Accelerates AI Preventive Care and Platform Strategy (Zacks)
09:04AM	AI-Driven Innovation Accelerates Tempus AI's Expansion Across MedTech (Zacks)
Feb-19-26 03:19PM	2 Tech Bets Cathie Wood is Quietly Trimming Right Now: Should You Too? (Barchart) +6.77%
02:01PM	Tempus Shares Jump On AI Cancer Tool (GuruFocus.com)
12:04PM	Tempus AI Stock Jumps As Mizuho Starts Coverage, Earnings Scheduled For Next Week (Benzinga)
09:40AM	Shopify, eBay upgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics (Zacks)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More (24/7 Wall St.)
Feb-18-26 11:52AM	Why Tempus AI Stock Is Up Today And What to Watch Before Next Weeks Earnings (24/7 Wall St.) +6.85%
11:12AM	What's Going On With Tempus AI Stock Today? (Benzinga)
09:41AM	Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy? (Zacks)
08:30AM	Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm (Business Wire)
Feb-17-26 04:44PM	Cathie Wood Adds 210K Shares to a Rising AI Bet With Upside of 102% (Barchart)
11:32AM	Market Movers: Citi Bullish on NVDA Heading into Earnings (24/7 Wall St.)
11:20AM	Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel (Zacks)
09:43AM	Dollar General downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
07:49AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Albemarle, BitGo Holdings, Chevron, Dollar General, Equifax, Shopify, Southwest Airlines, Visa, and More (24/7 Wall St.)
Feb-13-26 09:33AM	Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release? (Zacks)
Feb-12-26 09:22PM	Cathie Wood's Ark Scoops Up $12.4 Million In Beaten-Down Robinhood - Dumps More Airbnb Shares (Benzinga) -5.28%
04:05PM	Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform (Business Wire)
04:05PM	Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis LCS Software as a Medical Device in the United States (Business Wire)
Feb-11-26 11:13AM	HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? (Zacks)
Feb-10-26 09:54AM	Jim Cramer on Tempus (TEM): "It's Going to Go Back Down Again" (Insider Monkey)
08:30AM	Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24 (Business Wire)
Feb-04-26 10:17PM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
07:00AM	Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes (Business Wire)
Feb-02-26 07:00AM	Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield (Business Wire)
Feb-01-26 06:50PM	Here Are Congresswoman Nancy Pelosi's Initial Stock Moves in 2026: They Include Nvidia, Alphabet, and Amazon Stocks, and Others (Motley Fool)
08:30AM	Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones (Insider Monkey)
Jan-29-26 09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
08:47AM	TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom? (Zacks)
Jan-27-26 11:09AM	Nancy Pelosi Just Doubled Down on AI Again (24/7 Wall St.)
08:30AM	Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers (Business Wire)
Jan-26-26 08:56PM	Cathie Wood Bets Big On AI Trifecta: Ark Deploys $1.4 Million Across Medical, Autonomous Driving Sectors (Benzinga)
06:18PM	Pelosi's Bullish 2026 Buy List: AI, Power & Dividends (MarketBeat)
02:21PM	Nancy Pelosi Discloses New Stock Trades: Here's What She's Loading Up On - And What's She's Selling (Benzinga)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
10:20AM	Hims & Hers Scales Platform-Led Digital Healthcare Access and Care (Zacks)
09:40AM	How TEM Is Capitalizing on AI-Driven Pathology Market Growth (Zacks)
Jan-22-26 09:06PM	Cathie Wood Loads Up On This Robotaxi Stock, Ark Dumps Roku In Latest Trades (Benzinga)
12:42PM	HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling? (Zacks)
10:10AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jan-21-26 09:06PM	Cathie Wood Doubles Down On Netflix Despite Weak Guidance, Ark Invest Dumps This Social Media Stock (Benzinga)
04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
08:30AM	Tempus Announces the Launch of Paige Predict (Business Wire)
07:57AM	Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention (Zacks)
Jan-20-26 12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga) -5.05%
Jan-13-26 07:48AM	Tempus AI (TEM) Soars 15% on $1.1-Billion Deal (Insider Monkey)
07:30AM	TEM's Collab for Oncology Patient Population Is Gaining Attention (Zacks)
Jan-12-26 07:27PM	Why Tempus AI Stock Rose Today (Motley Fool)
04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
02:53PM	Why Tempus AI Stock Is Trading Higher On Monday? (Benzinga)
01:35PM	Why Tempus AI Stock Jumped on Monday? (GuruFocus.com)
01:08PM	Tempus AI's Pharma Momentum Accelerates (GuruFocus.com)

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEFKOFSKY ERIC P	CEO and Chairman	Apr 28 '26	Sale	51.13	166,250	8,500,623	8,841,783	Apr 30 04:30 PM
Eric Lefkofsky	Officer	Apr 28 '26	Proposed Sale	52.68	166,250	8,758,050		Apr 28 04:41 PM
JENNIFER DOUDNA	Director	Apr 15 '26	Proposed Sale	49.53	3,348	165,826		Apr 15 04:39 PM
LEFKOFSKY ERIC P	CEO and Chairman	Mar 26 '26	Sale	46.38	166,250	7,711,150	8,875,033	Mar 27 09:46 PM
Eric Lefkofsky	Officer	Mar 26 '26	Proposed Sale	46.76	166,250	7,773,850		Mar 26 04:27 PM
Epstein David R	Director	Mar 02 '26	Sale	50.69	250	12,672	25,801	Mar 04 04:30 PM
Rogers James William	Chief Financial Officer	Mar 02 '26	Sale	50.69	11,414	578,576	127,248	Mar 04 04:30 PM
JAMES ROGERS	Officer	Mar 02 '26	Proposed Sale	53.25	13,583	723,295		Mar 02 04:40 PM
DAVID R. EPSTEIN	Director	Mar 02 '26	Proposed Sale	53.25	870	46,328		Mar 02 04:38 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '26	Sale	58.87	166,250	9,787,605	8,908,283	Feb 20 09:45 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '26	Sale	59.05	13,587	802,312	1,989,626	Feb 20 09:45 PM
Phelps Erik	EVP, Chief Admin. Officer	Feb 19 '26	Sale	59.43	9,464	562,472	79,816	Feb 20 06:45 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 19 '26	Sale	59.05	2,902	171,363	41,159	Feb 20 06:45 PM
Polovin Andrew	EVP, Chief Legal Officer	Feb 20 '26	Sale	60.31	10,949	660,292	126,918	Feb 20 06:45 PM
Polovin Andrew	EVP, Chief Legal Officer	Feb 19 '26	Sale	59.05	8,143	480,844	99,447	Feb 20 06:45 PM
Fukushima Ryan	Chief Executive Officer, Data	Feb 19 '26	Sale	59.05	9,592	566,408	694,354	Feb 20 06:45 PM
Rogers James William	Chief Financial Officer	Feb 19 '26	Sale	59.05	10,084	595,460	101,166	Feb 20 06:45 PM
ERIK PHELPS	Officer	Feb 20 '26	Proposed Sale	59.96	3,823	229,227		Feb 20 04:28 PM
ANDREW POLOVIN	Officer	Feb 20 '26	Proposed Sale	59.96	10,949	656,502		Feb 20 04:25 PM
Ryan M. Bartolucci	Officer	Feb 19 '26	Proposed Sale	56.16	2,902	162,976		Feb 19 09:24 PM
Andrew Polovin	Officer	Feb 19 '26	Proposed Sale	56.16	8,143	457,311		Feb 19 09:22 PM
Eric Paul Lefkofsky	Officer	Feb 19 '26	Proposed Sale	56.16	13,587	763,046		Feb 19 09:20 PM
Ryan Fukushima	Officer	Feb 19 '26	Proposed Sale	56.16	9,592	538,687		Feb 19 09:17 PM
Erik Phelps	Officer	Feb 19 '26	Proposed Sale	56.16	5,650	317,304		Feb 19 09:15 PM
James William Rogers	Officer	Feb 19 '26	Proposed Sale	56.16	10,084	566,317		Feb 19 09:13 PM
ERIK PHELPS	Officer	Feb 19 '26	Proposed Sale	56.16	3,814	214,194		Feb 19 04:43 PM
Eric Lefkofsky	Officer	Feb 19 '26	Proposed Sale	56.16	166,250	9,336,600		Feb 19 04:08 PM
Tempus AI, Inc.	10% Owner	Nov 18 '25	Buy	7.67	64,750	496,632	12,783,550	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 25 '25	Buy	10.62	23,600	250,665	12,918,346	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 22 '25	Buy	8.93	28,000	250,040	13,039,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 21 '25	Buy	9.40	26,499	249,190	12,869,521	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 24 '25	Buy	9.87	25,225	248,971	12,894,746	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 19 '25	Buy	8.12	30,645	248,837	12,814,195	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 20 '25	Buy	8.63	28,827	248,777	12,843,022	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 17 '25	Buy	7.86	31,650	248,769	12,949,996	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 19 '25	Buy	8.39	29,641	248,688	13,011,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 18 '25	Buy	7.91	31,430	248,611	12,981,426	Feb 13 05:24 PM
Epstein David R	Director	Feb 02 '26	Sale	59.41	370	21,982	26,051	Feb 04 04:30 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jan 28 '26	Sale	65.56	166,250	10,899,207	8,941,533	Jan 30 04:15 PM
Eric Lefkofsky	Officer	Jan 28 '26	Proposed Sale	66.81	166,250	11,107,162		Jan 28 04:21 PM
Fukushima Ryan	Chief Operating Officer	Jan 05 '26	Sale	64.26	5,000	321,300	148,808	Jan 07 06:25 PM
Doudna Jennifer A	Director	Jan 02 '26	Sale	60.17	1,250	75,212	22,702	Jan 06 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Dec 18 '25	Sale	63.99	166,250	10,638,478	8,974,783	Dec 22 05:41 PM
Eric Lefkofsky	Officer	Dec 18 '25	Proposed Sale	64.61	166,250	10,741,413		Dec 18 04:39 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Dec 16 '25	Sale	67.42	1,302	87,781	89,280	Dec 18 04:15 PM
ERIK PHELPS	Officer	Dec 16 '25	Proposed Sale	68.67	1,302	89,408		Dec 16 04:29 PM
Rogers James William	Chief Financial Officer	Dec 11 '25	Sale	73.20	19,966	1,461,479	111,250	Dec 12 04:30 PM
JAMES ROGERS	Officer	Dec 11 '25	Proposed Sale	75.07	19,966	1,498,848		Dec 11 04:23 PM
Frederick Wayne A.I.	Director	Dec 05 '25	Sale	77.23	3,675	283,820	24,836	Dec 09 04:15 PM
WAYNE FREDERICK	Director	Dec 05 '25	Proposed Sale	77.23	3,675	283,802		Dec 05 04:15 PM
Epstein David R	Director	Dec 01 '25	Sale	75.55	250	18,888	26,421	Dec 03 04:50 PM
Fukushima Ryan	Chief Operating Officer	Dec 01 '25	Sale	75.72	5,000	378,620	153,808	Dec 03 04:50 PM
Doudna Jennifer A	Director	Dec 01 '25	Sale	75.55	676	51,072	23,952	Dec 03 04:50 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 24 '25	Sale	74.10	166,250	12,319,125	9,008,033	Nov 25 04:30 PM
Polovin Andrew	EVP and General Counsel	Nov 24 '25	Sale	75.00	12,874	965,550	107,590	Nov 25 04:30 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	70.40	166,250	11,703,285		Nov 24 06:11 PM
ANDREW POLOVIN	Officer	Nov 24 '25	Proposed Sale	70.29	12,874	904,913		Nov 24 04:29 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 20 '25	Sale	68.97	166,250	11,466,099	9,041,283	Nov 20 07:56 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 18 '25	Sale	65.54	16,829	1,102,944	2,003,213	Nov 20 07:56 PM
Rogers James William	Chief Financial Officer	Nov 18 '25	Sale	65.54	7,257	475,611	131,216	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 19 '25	Sale	68.06	6,387	434,707	120,464	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 18 '25	Sale	65.54	5,205	341,126	126,851	Nov 20 07:05 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Nov 18 '25	Sale	65.54	3,533	231,547	90,582	Nov 20 07:05 PM
Fukushima Ryan	Chief Operating Officer	Nov 18 '25	Sale	65.54	10,099	661,870	829,081	Nov 20 07:05 PM
Bartolucci Ryan M	Chief Accounting Officer	Nov 18 '25	Sale	65.54	1,834	120,197	44,061	Nov 20 07:05 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	69.09	166,250	11,486,212		Nov 20 04:46 PM
ANDREW POLOVIN	Officer	Nov 19 '25	Proposed Sale	66.77	6,387	426,460		Nov 19 04:22 PM
Ryan M. Bartolucci	Officer	Nov 18 '25	Proposed Sale	66.39	1,834	121,759		Nov 18 07:09 PM
Ryan Fukushima	Officer	Nov 18 '25	Proposed Sale	66.39	10,099	670,473		Nov 18 07:08 PM
Eric Paul Lefkofsky	Officer	Nov 18 '25	Proposed Sale	66.39	16,829	1,117,277		Nov 18 07:07 PM
Andrew Polovin	Officer	Nov 18 '25	Proposed Sale	66.39	5,205	345,560		Nov 18 07:05 PM
James William Rogers	Officer	Nov 18 '25	Proposed Sale	66.39	7,257	481,792		Nov 18 07:04 PM
Erik Phelps	Officer	Nov 18 '25	Proposed Sale	66.39	3,533	234,556		Nov 18 07:03 PM
Doudna Jennifer A	Director	Nov 11 '25	Sale	71.45	1,926	137,613	24,628	Nov 13 04:15 PM
JENNIFER DOUDNA	Director	Nov 11 '25	Proposed Sale	71.78	3,852	276,497		Nov 12 07:03 AM
Fukushima Ryan	Chief Operating Officer	Nov 03 '25	Sale	89.03	5,000	445,160	125,000	Nov 05 04:15 PM
Epstein David R	Director	Nov 03 '25	Sale	90.00	370	33,300	26,671	Nov 05 04:15 PM
VANESSA L KUBO	Officer	Nov 03 '25	Proposed Sale	89.85	20,000	1,797,000		Nov 03 04:26 PM
DAVID R. EPSTEIN	Director	Nov 03 '25	Proposed Sale	89.85	990	88,952		Nov 03 04:25 PM
LEFKOFSKY ERIC P	CEO and Chairman	Oct 28 '25	Sale	89.11	332,500	29,629,006	9,074,532	Oct 30 04:31 PM
Eric Lefkofsky	Officer	Oct 28 '25	Proposed Sale	91.58	332,500	30,450,350		Oct 28 04:09 PM
Fukushima Ryan	Chief Operating Officer	Oct 06 '25	Sale	92.32	5,000	461,606	130,000	Oct 08 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Sep 25 '25	Sale	76.56	332,500	25,457,014	9,141,032	Sep 29 04:33 PM
Eric Lefkofsky	Officer	Sep 25 '25	Proposed Sale	84.13	332,500	27,973,225		Sep 25 07:04 PM
Fukushima Ryan	Chief Operating Officer	Sep 02 '25	Sale	75.80	10,000	758,028	135,000	Sep 04 04:15 PM
Epstein David R	Director	Sep 02 '25	Sale	73.64	250	18,410	27,041	Sep 04 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 27 '25	Sale	74.10	332,500	24,637,581	9,207,533	Aug 29 05:13 PM
Leonsis Theodore	Director	Aug 26 '25	Sale	75.83	20,000	1,516,600	66,756	Aug 28 04:15 PM
Eric Lefkofsky	Officer	Aug 27 '25	Proposed Sale	75.90	332,500	25,236,750		Aug 27 04:19 PM
Leonsis Theodore	Director	Aug 26 '25	Proposed Sale	75.83	20,000	1,516,650		Aug 26 01:27 PM
Polovin Andrew	EVP and General Counsel	Aug 19 '25	Sale	74.65	5,398	402,982	132,056	Aug 21 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Aug 19 '25	Sale	74.65	3,664	273,532	94,115	Aug 21 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 19 '25	Sale	74.65	17,458	1,303,307	2,020,042	Aug 21 04:15 PM
Fukushima Ryan	Chief Operating Officer	Aug 19 '25	Sale	74.65	17,460	1,303,456	839,180	Aug 21 04:15 PM
Rogers James William	Chief Financial Officer	Aug 19 '25	Sale	74.65	7,528	561,994	138,473	Aug 21 04:15 PM
Bartolucci Ryan M	Chief Accounting Officer	Aug 19 '25	Sale	74.65	1,904	142,141	45,895	Aug 21 04:15 PM
Erik Phelps	Officer	Aug 19 '25	Proposed Sale	78.45	3,664	287,441		Aug 20 07:19 AM
Andrew Polovin	Officer	Aug 19 '25	Proposed Sale	78.45	5,398	423,473		Aug 20 07:17 AM
Ryan Fukushima	Officer	Aug 19 '25	Proposed Sale	78.45	17,460	1,369,737		Aug 20 07:15 AM
Eric Paul Lefkofsky	Officer	Aug 19 '25	Proposed Sale	78.45	17,458	1,369,580		Aug 20 07:14 AM

Open in Screener

PFE

Pfizer Inc

May 08 • 04:00PM ET

25.68

-0.80 -3.02 %

Healthcare • Drug Manufacturers - General • USA • Large • NYSE

Peers: BMY SNY AZN MRK GSK ABBV TAK JNJ LLY AMGN

| Held by: VTI VOO IVV SPY VTV XLV VYM DVY VHT FDL

Index	S&P 500	P/E	19.69	EPS (ttm)	1.30	Insider Own	0.06%	Shs Outstand	5.70B	Perf Week	-2.47%
Market Cap	146.36B	Forward P/E	9.03	EPS next Y	2.84	Insider Trans	0.00%	Shs Float	5.70B	Perf Month	-5.66%
Enterprise Value	198.04B	PEG	-	EPS next Q	0.68	Inst Own	68.15%	Short Float	2.34%	Perf Quarter	-5.66%
Income	7.46B	P/S	2.31	EPS this Y	-7.95%	Inst Trans	1.49%	Short Ratio	3.45	Perf Half Y	4.35%
Sales	63.31B	P/B	1.62	EPS next Y	-4.02%	ROA	3.60%	Short Interest	133.41M	Perf YTD	3.13%
Book/sh	15.81	P/C	11.19	EPS next 5Y	-8.64%	ROE	8.29%	52W High	28.75 -10.66%	Perf Year	11.80%
Cash/sh	2.29	P/FCF	15.43	EPS past 3/5Y	-37.19% -3.57%	ROIC	4.95%	52W Low	21.97 16.89%	Perf 3Y	-33.59%
Dividend Est.	1.75 (6.83%)	EV/EBITDA	8.35	Sales past 3/5Y	-14.56% 8.48%	Gross Margin	65.16%	Volatility	2.10% 2.05%	Perf 5Y	-35.12%
Dividend TTM	1.72 (6.70%)	EV/Sales	3.13	EPS Y/Y TTM	-5.39%	Oper. Margin	27.08%	ATR (14)	0.59	Perf 10Y	-19.30%
Dividend Ex-Date	May 08, 2026	Quick Ratio	0.94	Sales Y/Y TTM	1.36%	Profit Margin	11.79%	RSI (14)	35.22	Recom	2.50
Dividend Gr. 3/5Y	2.23% 2.37%	Current Ratio	1.25	EPS Q/Q	-9.78%	SMA20	-4.13%	Beta	0.31	Target Price	29.10
Payout	126.85%	Debt/Eq	0.72	Sales Q/Q	5.37%	SMA50	-5.09%	Rel Volume	0.96	Prev Close	26.48
Employees	75000	LT Debt/Eq	0.67	Earnings	May 05 BMO	SMA200	-0.17%	Avg Volume	38.66M	Price	25.68
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.92% 4.41%	Trades		Volume	37,294,277	Change	-3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Upgrade	Argus	Hold → Buy	$35
Feb-25-26	Initiated	RBC Capital Mkts	Underperform	$25
Feb-20-26	Initiated	Barclays	Underweight	$25
Feb-12-26	Downgrade	Daiwa Securities	Outperform → Neutral	$27
Jan-07-26	Resumed	UBS	Neutral	$25
Dec-02-25	Resumed	Citigroup	Neutral	$26
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$30
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50

Show Previous Ratings

May-08-26 01:50PM	Nasdaq, S&P 500 Enjoy Another Record-Breaking Week (Schaeffer's Research)
11:42AM	GLP-1 battle heats up between Eli Lilly and Novo Nordisk (Yahoo Finance Video)
May-06-26 02:06PM	Pfizer CEO Backs Trump's CDC Pick After Vaccine Policy Upheaval (GuruFocus.com)
09:15AM	Can Pfizer Stock Outrun A $17B Revenue Void? (Trefis)
03:00AM	CellCentric raises $220M for a transformative multiple myeloma medicine (BioPharma Dive)
04:54PM	Loading…
May-05-26 04:54PM	Pfizer Inc. Q1 2026 Earnings Call Summary (Moby)
03:56PM	Pfizer CEO Says Digging Out of Post-Covid Hole Will Take a Few More Years (The Wall Street Journal)
02:41PM	Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms (GuruFocus.com)
01:30PM	Pfizer pins post 2028 return to growth on new obesity and cancer drugs (Reuters)
12:41PM	Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance (Proactive)
12:30PM	Chicken or the Egg? Why We Need to Rethink Data and Funding in Startups (Entrepreneur)
11:05AM	Pfizer tops Q1 expectations on growth from newer products (InvestorsHub)
10:44AM	2 Trendlines in Focus For Pfizer Stock After Earnings (Schaeffer's Research)
09:54AM	BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. (Barrons.com)
09:02AM	Stock Futures Higher on Cooling Oil, Upbeat Earnings (Schaeffer's Research)
08:53AM	Loading…
08:53AM	Why Pfizer's 'Mild' First-Quarter Report Likely Won't Satisfy Skeptics (Investor's Business Daily)
08:45AM	Pfizer Q1 2026 earnings beat estimates on newer drug growth (Quartz)
08:35AM	Pfizer Posts Better-Than-Expected Revenue, Profit (The Wall Street Journal)
08:00AM	How Pfizers CEO says he uses AI to make decisions (CNN Business)
07:34AM	Pfizer beats first quarter estimates on strong product growth (Investing.com)
07:23AM	Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending (The Wall Street Journal)
07:06AM	Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates (Barrons.com)
06:54AM	Pfizer: Q1 Earnings Snapshot (Associated Press)
06:45AM	Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance (Business Wire)
04:59AM	AMD headlines Tuesday's earnings slate (MarketWatch)
May-04-26 07:55PM	Review & Preview: War Redux (Barrons.com)
07:00PM	AMD and Pfizer earnings, job openings, Fedspeak: What to Watch (Yahoo Finance Video)
05:06AM	Protein degraders gain speed as Arvinas scores landmark approval (Pharma Voice)
May-01-26 10:50AM	Eli Lilly Stocks Path To 30% Upside (Trefis)
07:30AM	Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best (GuruFocus.com)
01:00PM	Loading…
Apr-30-26 01:00PM	The Week Ahead: Employment Data, Fed Speeches (Schaeffer's Research)
12:08PM	Thinning revenues: inside the $14bn Eliquis patent cliff (Pharmaceutical Technology)
11:41AM	Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales (Reuters)
Apr-29-26 12:59PM	Pfizer protects $6.4bn heart disease blockbuster from generics, for now (Pharmaceutical Technology)
07:21AM	FDA tests out real-time clinical trials; AbbVie closes in on a KRAS biotech (BioPharma Dive)
06:45AM	Pfizers ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma (Business Wire)
03:09AM	OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... (GuruFocus.com)
02:58AM	AWS CEO Matt Garman sees huge business opportunity for Amazon in AI-powered software: Everything is going to be remade (Fortune)
Apr-28-26 10:17AM	Pfizer Reaches Three Settlement Agreements for VYNDAMAX (Business Wire)
08:28AM	Pfizer deals extend patent life for a top-selling rare disease drug (BioPharma Dive)
Apr-24-26 04:55PM	CureVac sues Moderna for patent infringement over COVID-19 vaccines (Reuters)
01:34PM	Bristol Myers, Pfizer Bring Eliquis to Cost Plus at $345 Monthly (GuruFocus.com)
11:00AM	Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims (Yahoo Finance Video)
06:59AM	Bristol Myers Squibb and Pfizer to Make Eliquis (apixaban) Available via Mark Cuban Cost Plus Drug Company (Business Wire)
Apr-23-26 05:49PM	Regeneron Shares Up on Trump Drug Pricing Deal (Barrons.com)
02:27AM	Richest countries in 2026: New measure of wealth pushes France and Germany out of top ten (Euronews)
Apr-22-26 04:45PM	Pfizer Declares Second-Quarter 2026 Dividend (Business Wire)
11:01AM	Pfizer CFO Dave Denton on Oncology, Obesity, and Pfizers Next Growth Cycle (NYSE)
Apr-21-26 12:23PM	Eli Lilly eyes Kelonia Therapeutics in $7B deal with $3.25B to be paid up front. How to invest early to grow your wealth (Moneywise)
11:51AM	Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026 (Business Wire)
06:29AM	Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy (Pharmaceutical Business Review)
Apr-20-26 10:47AM	Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. (Barrons.com)
06:45AM	U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility (PR Newswire)
Apr-17-26 04:13PM	Why Is Abbott Stock Trending Lower? (Trefis)
Apr-13-26 11:43AM	How Eli Lilly Stock Rises To $2,000 (Trefis)
Apr-11-26 08:01PM	How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results (Quartz)
Apr-10-26 08:11PM	Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing (Quartz)
Apr-09-26 10:00AM	Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders (Business Wire)
Apr-08-26 12:44PM	Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Drug Pipeline (GuruFocus.com)
Apr-07-26 05:47PM	The $190 Billion 'Diabesity' Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts. (Barrons.com)
Apr-02-26 04:05PM	Trump slaps steep tariffs on patented drug imports (Supply Chain Dive)
11:37AM	Boost Pfizer's Already Hefty 6% Dividend Yield With A Covered Call (Investor's Business Daily)
08:01AM	JNJ Stocks 60% Breakout: Why Wall Street is Torn (Trefis)
Apr-01-26 04:07PM	Why 2026 Is Biotech's Comeback Year (Barrons.com)
04:05PM	Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations (The Wall Street Journal)
10:02AM	Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer - And Plunges (Investor's Business Daily)
09:30AM	Pfizer Pulls Back From South San Francisco (GuruFocus.com)
04:00AM	Will Pfizers Lyme disease gamble pay off or set the space back? (Pharma Voice)
Mar-31-26 03:45PM	$2 Billion Bayer Verdict: What the Roundup Decision Means for MAHA (Exec Edge)
Mar-30-26 10:44AM	Pharma Stocks Pfizer, GSK Offer Defensive Plays in an Uncertain Market: Charts (Barrons.com)
09:37AM	Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. What It Means for the Stock. (Barrons.com)
09:17AM	Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises. (Barrons.com)
02:03AM	Connecting Excellence Group appoints chief performance and growth officer (Proactive)
Mar-27-26 11:40AM	Consecutive approvals of Opdivo for Hodgkins lymphoma to boost sales growth (Clinical Trials Arena)
Mar-26-26 01:30AM	22 S&P 500 Stocks Yield More Than 5%. 6 That Are Worth Buying. (Barrons.com)
Mar-24-26 11:02AM	Pfizer CFO Dave Denton Highlights Firms Recent Oncology Milestones (NYSE)
10:39AM	Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook (GuruFocus.com)
10:00AM	Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts (Business Wire)
05:57AM	Immutrin raises $87M to advance drug for progressive heart disease (BioPharma Dive)
Mar-23-26 02:31PM	Pfizer-Valneva Lyme disease vaccine falls short as low cases skew results (Clinical Trials Arena)
01:00PM	Stocks Rise, Oil Falls as Trump Eases Iran Threats: Markets Wrap (Bloomberg)
12:46PM	Pfizer's Lyme Vaccine Shows Strong Efficacy, but Misses Mark in Study (The Wall Street Journal)
09:54AM	Mixed results for Lyme disease vaccine hit Valneva shares (AFP)
08:06AM	Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results (BioPharma Dive)
08:00AM	Telescope Innovations Announces Expansion of Consulting Role for Dr. Joel M. Hawkins, Industry Leader in Process Chemistry Automation (TMX Newsfile)
07:07AM	Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial (MarketWatch)
07:02AM	Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial (The Wall Street Journal)
06:45AM	Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial (Business Wire)
Mar-22-26 09:00PM	IP Group PLC (IPZYF) Full Year 2025 Earnings Call Highlights: Strong NAV Growth Amid Market ... (GuruFocus.com)
Mar-20-26 04:30PM	Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC (Business Wire)
Mar-19-26 09:47AM	ImmuPharma, Ilika, Coinsilium Group, IP Group, Team Internet Group - Small Cap Week in Review (Proactive)
07:37AM	Pfizer aims for wider use of PARP drug in prostate cancer with new data (BioPharma Dive)
07:30AM	The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients (Fortune)
06:45AM	TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer (Business Wire)
Mar-18-26 05:00PM	Valneva SE (INRLF) Full Year 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
02:29PM	Analysis-TrumpRx lists many medicines at prices higher than paid in UK (Reuters)
Mar-17-26 03:01PM	Pfizer Reports Positive Mid-Stage Breast Cancer Trial Results (GuruFocus.com)
07:56AM	Bicycle to lay off 30% of staff, pivot away from Padcev challenger (BioPharma Dive)
07:15AM	Pfizers Ibrance successor moves forward with new study data (BioPharma Dive)
06:45AM	Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer (Business Wire)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAHNI PAYAL	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	82,816	Feb 27 06:35 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 25 '26	Option Exercise	33.82	122,907	4,156,715	282,186	Feb 27 06:35 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 25 '26	Option Exercise	33.82	17,558	593,812	29,744	Feb 27 06:35 PM
BOURLA ALBERT	Chairman & CEO	Feb 25 '26	Option Exercise	33.82	491,626	16,626,791	864,215	Feb 27 06:34 PM
Fonseca Lidia	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	101,579	Feb 27 06:34 PM
McDermott Michael	Executive Vice President	Feb 25 '26	Option Exercise	33.82	37,925	1,282,624	114,534	Feb 27 06:34 PM
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your Finviz experience